Altimmune Q1 2024 GAAP EPS $(0.34) Beats $(0.36) Estimate, Sales $5.000 Down From $21.000K YoY
Portfolio Pulse from Benzinga Newsdesk
Altimmune reported its Q1 2024 earnings with a GAAP EPS of $(0.34), surpassing the $(0.36) estimate. However, its sales significantly decreased to $5.000 from $21.000K in the previous year.

May 09, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Altimmune's Q1 2024 earnings exceeded EPS estimates but experienced a significant decline in sales year-over-year.
While beating EPS estimates typically has a positive impact on stock prices, the substantial decrease in sales year-over-year could raise concerns about the company's revenue growth and future profitability. This mixed result may lead to neutral short-term stock price movement as investors weigh the positive EPS performance against the negative sales trend.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100